The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AbbVie; Agenus; Ambry Genetics; Amgen; Arquer Diagnostics; AstraZeneca; Celsion; Clovis Oncology; Corcept Therapeutics; Eisai; Elevar Therapeutics; Genentech/Roche; GOG Foundation; Immunogen; INXMED; Iovance Biotherapeutics; Janssen; Mersana; Myriad Genetics; Novartis; Novocure; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sumitomo Dainippon Pharma Oncology/BBI; Takeda; Tarveda Therapeutics; Tesaro/GSK; Toray Industries
Research Funding - AbbVie; Agenus; Ajinomoto; Amgen; Array Biopharma; AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; EMD Serono; Ergomed; Genentech/Roche; GenMab; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen; Ludwig Institute for Cancer Research; Merck; Mersana; New Mexico Cancer Care Alliance; Novocure; Regeneron; Seagen; Stemcentrix; Sumitomo Dainippon Pharma Oncology/BBI; Tesaro/GSK; TRACON Pharma; VentiRx
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)
 
Sara Bouberhan
Consulting or Advisory Role - Immunogen
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
 
Roisin Eilish O'Cearbhaill
Honoraria - Curio Science; GlaxoSmithKline; MJH Life Sciences; MJH/PER
Consulting or Advisory Role - Aptitude Health; Bayer; Carina Biotech; Fresenius Kabi; GlaxoSmithKline; GOG Foundation; Immunogen; R-Pharm; Regeneron; Seagan
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca/Merck (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Ludwig Institute for Cancer Research (Inst); Merck/Genentech (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Syndax (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)
Travel, Accommodations, Expenses - Gathering Around Cancer; Hitech Health; Society of Gynecologic Oncology
Other Relationship - JAMA Oncology
(OPTIONAL) Uncompensated Relationships - Children's Medical Research Foundation (CMRF)
 
David M. O'Malley
No Relationships to Disclose
 
Konstantinos Papadamitriou
No Relationships to Disclose
 
David Schröder
No Relationships to Disclose
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - Regeneron (Inst)
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Mary Jane Peterman
Employment - Regeneron
Stock and Other Ownership Interests - Merck; Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Priscila Hermont Goncalves
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Tamara Schmidt
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Min Zhu
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Thomas S. Uldrick
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Elizabeth Miller
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron